Tirzepatide calculators

Tirzepatide vials are usually 10 mg or 15 mg, larger than semaglutide because the doses are larger. 2 mL of bacteriostatic water on a 10 mg vial gives 5 mg/mL — a 2.5 mg starter dose pulls exactly 0.5 mL or 50 units. Clean, repeatable, easy to draw weekly.

One Tirzepatide-specific failure mode worth knowing before you use the reconstitution math: Underestimating doses-per-vial on a high-strength vial because the vial looks small even though it contains many weeks of supply. How is tirzepatide reconstituted? By drawing a measured volume of bacteriostatic water and injecting it slowly into the lyophilized vial through the rubber stopper, then swirling — not shaking — until the powder fully dissolves. Diluent volume choices typically range from 2 to 5 mL depending on vial strength and preferred per-dose unit count.

Vial size, diluent volume, and dose are the three inputs that genuinely change the answer. Doses-per-vial is a derived output — it's the vial mg divided by the dose mg, rounded down. The most common edge case is a tiny dose: at very high concentration, a 0.1 mL draw is only a few units on the syringe, which is hard to read accurately. If your unit count drops below five, consider reconstituting the next vial with more BAC water so each dose covers a larger volume.

The illustrative example on this page assumes a 10 mg vial reconstituted with 2 mL of bacteriostatic water. That gives a concentration of 5 mg per mL, which makes a 2.5 mg illustrative dose exactly 0.5 mL — 50 units on a U-100 syringe. That is on the larger end of typical injection volumes; many users prefer 3 mL of diluent on a 10 mg vial to get more total doses per vial at smaller individual draws.

Higher-strength tirzepatide vials — 30 mg and above — are increasingly common in the research market. These benefit even more from extra diluent because each individual dose is still small relative to the vial, and a 4 or 5 mL reconstitution makes per-dose draws much easier to read on the syringe.

When reconstituting, researchers must plan for the mechanical limitations of administration hardware, a factor most prominent at higher dose tiers. For example, a 10 mg vial reconstituted with 2 mL of diluent yields a concentration of 5 mg/mL. A 2.5 mg illustrative dose from this solution is a standard 0.5 mL draw, or 50 units. However, a 15 mg dose from the same solution would calculate to a 3 mL volume. This large volume exceeds the maximum capacity of a standard 1-mL U-100 insulin syringe, making it impossible to draw in a single administration. To manage this logistical issue, researchers may document using a larger sterile syringe (e.g., a 3 mL syringe) or may plan reconstitution with more diluent to yield a less concentrated solution where the required dose fits within a 1 mL volume.